Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting
June 03 2022 - 1:00AM
Oxurion Announces Two Upcoming Presentations at The Macula Society
45th Annual Meeting
Leuven, BELGIUM,
Boston, MA, US – JUNE 3,
2022 –
Oxurion NV (Euronext
Brussels: OXUR), a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, with clinical stage assets in vascular
retinal disorders, today announced that two abstracts will be
presented at The Macula Society 45th Annual Meeting, June 8 -11,
2022 in Berlin, Germany.
THR-149 is a potent plasma kallikrein inhibitor
being developed as a potential new standard of care for the up to
50% of diabetic macular edema (DME) patients showing suboptimal
response to anti-VEGF therapy. Oxurion is evaluating THR-149 for
the treatment of DME in Part B, the second part of its two-part
Phase 2 KALAHARI trial.
TITLE: KALAHARI: Part A Results
of the Phase 2 Study of THR-149, a Plasma Kallikrein Inhibitor, in
Subjects with DME Responding Sub optimally to anti-VEGF
Treatment
PRESENTER: Shree K. Kurup, MD,
Dept. of Ophthalmology, University Hospitals, Cleveland, OH
PRESENTATION DATE AND TIME:
Friday, June 10, 2022, 7:50 a.m. CET
THR-687 is a highly selective pan-RGD integrin
antagonist that Oxurion had been developing as a first line therapy
for DME patients. Recently released data from Part A, the first
part of its two-part Phase 2 INTEGRAL trial showed THR-687 to be
safe and well tolerated with no serious adverse events and none of
the patients requiring rescue medication through Month 3, however,
there was insufficient evidence of efficacy on the key endpoints
(Best-Corrected Visual Acuity and Central Subfield Thickness). As a
result, Oxurion has decided not to advance THR-687 to Part B of the
INTEGRAL trial.
TITLE: THR-687, a Potent and
Highly Selective RGD Integrin Inhibitor in Development for the
Treatment of Diabetic Macular Edema
PRESENTER: Francesco Bandello,
Professor and Chairman of the Department of Ophthalmology,
VitaSalute, Milan, Italy
PRESENTATION DATE AND TIME:
Thursday, June 9, 2022, 8:44 a.m. CET
About
OxurionOxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to 50% of DME patients showing suboptimal response
to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium,
with corporate operations in Boston, MA. More information is
available at www.oxurion.com.
For more information, please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel:
+32 16 75 13 10tom.graney@oxurion.com Michaël DillenChief
Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com |
USConway Communications Beth
Kurth bkurth@conwaycommsir.com Westwicke, an ICR
CompanyChristopher BrinzeyTel: +1 617 835
9304chris.brinzey@westwicke.com |
- OXUR Macula Society Curtain Raiser 2022.0603
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Apr 2024 to May 2024
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From May 2023 to May 2024